STE — STERIS plc

Wall Street is broadly bullish on STE (12 Buy ratings, 2 Hold, consensus target $271.33), but the market itself is cautious: the stock is down about 6.7% year-to-date and lagging the S&P 500. Q1 FY27 adjusted EPS beat consensus, yet the FCF margin fell to 18.7% from 23.5% a year ago, and management simultaneously announced a large multi-year investment in North Carolina, which investors are weighing against long-term growth.

Revenue has grown steadily from $1.24B in Sep-2023 to $1.49B in Jun-2026, with YoY growth in the high single digits; the latest quarter grew 7.3%. Diluted EPS has climbed from $1.16 to $2.04 over that period, and operating margin has expanded from about 15.5% in Sep-2023 to 19.1% in Jun-2026. The one notable blemish is Q1 FY27 operating cash flow falling to $367M from $420M a year earlier, which pushed FCF down to $279.6M from $326.4M; that looks more like timing and heavier investment than a demand break, but it is a real caution flag.

As of 2026-08-27, STE looks fairly valued to slightly cheap by its own history. The trailing P/E of 28.4x is far below its 5-year average of 79.5x, and the P/S of 3.76x is below the 5-year average of 4.36x. More meaningfully, the forward P/E on next-fiscal-year estimated EPS of $11.21 is about 20.8x, a reasonable multiple for a high-margin healthcare compounder with steady revenue growth and expanding operating margins. It is not a deep-value stock, but it is not expensive either.

The stock is currently priced for skepticism about near-term free cash flow rather than for strong growth. At roughly 21x forward earnings, the market is not paying up for margin expansion or the potential payoff from the $600M chemistry center. If STERIS delivers on full-year margin expansion and EPS toward the $11.21 consensus, the stock has room to re-rate toward the $270s. If the capex program keeps dragging FCF for several quarters, the multiple can stay stuck in the current range. The earnings trajectory is better than the price action suggests.

As of 2026-08-27, RSI-14 is 53.0, so STE is neither overbought nor oversold. Price is 0.8% below its 20-day SMA, 4.8% above its 50-day SMA, and 0.4% below its 200-day SMA. This is a consolidating, range-bound picture rather than a clear trend. A decisive move back above the 200-day and through the mid-$240s would improve near-term momentum, while support near the $195 52-week low is a long way down.

• Hospital procedure volumes and global healthcare utilization remain structurally supportive for STERIS's consumables and sterilization services.
• Higher-for-longer interest rates raise the cost and scrutiny of large capex projects like the $600M North Carolina investment.
• Persistent raw-material and labor inflation requires continued pricing power to protect gross margins around 44-45%.
• Healthcare has lagged the broader market in 2026, keeping medical-supply valuations below historical averages.
• Payer and hospital budget constraints remain a check on capital equipment purchases even while recurring consumable demand holds up.

• Q2 FY2027 earnings expected around November 4, 2026, with consensus EPS of $2.68 and a key update on margin and FCF guidance.
• Progress milestones at the $600M North Carolina Formulated Chemistries Center over the next 2-3 years, including early revenue contribution.
• Continued shareholder returns: quarterly dividend raised to $0.69 on July 30, 2026, alongside ongoing buybacks.
• Analyst price targets clustered at $269-$275; a clean quarter could trigger multiple expansion back toward that range.

• Execution risk on the $600M greenfield investment: cost overruns, delays, or a slow ramp would pressure FCF and returns for years.
• Q1 FY27 FCF margin fell to 18.7% from 23.5% YoY; if this persists, STERIS could be repriced as a more capital-intensive, lower-return business.
• Softening hospital procedure volumes or payer pricing pressure would hit high-margin consumables and AST services.
• Raw-material inflation and supply-chain disruption could outpace pricing offset measures.
• Multiple de-rating risk if organic growth falls below mid-single digits or operating margin expansion stalls.

STERIS is a high-quality, low-debt healthcare compounder with steady high-single-digit revenue growth, expanding operating margins, and a resilient recurring-revenue base. At $232.97, it is not a screaming bargain, but the forward multiple is reasonable and the market is not paying up for growth. The main swing factor is the $600M capex program: if it is executed well, the stock likely heads toward the $270s; if it drags FCF, the current range could persist. For a long-term investor, this is a reasonable hold or accumulate-on-weakness rather than an urgent buy.

Applied a 23.5x forward P/E to next-fiscal-year estimated EPS of $11.21, justified by STERIS's expanding operating margins, low debt, high-single-digit revenue growth, and sub-1.2 PEG history. This produces $263.34, a modest premium to the current price but below the Wall Street consensus target of $271.33.